BTL Aesthetics Emsella

EMS/HIFEM muscle stimulation · HIFEM chair for pelvic floor

CurrentFDA ClearedBe the first to review

What it's actually cleared for: Electromagnetic pelvic floor stimulation for rehabilitation of weak pelvic muscles and treatment of urinary incontinence

Last verified: August 6, 2026 · How we verify

New: $80k–$100k|Used: $30k–$60kmarket estimate, no email required

Save device

Bottom line

The rare aesthetic-adjacent device with a real medical indication, zero consumables, and zero staff hands-on time — the patient sits fully clothed on the chair for 28 minutes while it runs. Unit economics are excellent if, and only if, you can generate incontinence patient flow; it's a marketing-dependent device, and chairs gather dust in practices that expected walk-in demand. Pairs brilliantly with EmpowerRF, Emsculpt ecosystems, and any practice serving women 40+. Negotiate hard on ~$85k-100k list; used chairs are widely available.

Overview

Seated pelvic-floor muscle stimulation

How it works

The science

HIFEM — a coil in the seat induces supramaximal pelvic floor contractions, thousands per session ("11,000 Kegels" in the marketing), far beyond voluntary exercise. Mechanism: neuromuscular re-education and strengthening for stress, urge, and mixed urinary incontinence, with published response rates around 75-95% patient-reported improvement across a 6-session course. Secondary marketed uses (sexual wellness, postpartum, post-prostatectomy support) ride the same mechanism. Non-invasive, no disrobing, no downtime.

Patented tech

HIFEM is BTL's patented and litigiously defended electromagnetic stimulation technology (same family as Emsculpt) — a high-power pulsed magnetic coil firing motor neurons; the patent moat is real and BTL sues copycats aggressively.

Origin

BTL Industries — Czech-founded, production in the Czech Republic and Bulgaria; verify country-of-origin labeling on your unit.

FDA & regulatory status

FDA ClearedCleared via 510(k)

What it's actually cleared for:

Electromagnetic pelvic floor stimulation for rehabilitation of weak pelvic muscles and treatment of urinary incontinence

510(k) numbers

K181497

Regulatory data is compiled from public FDA 510(k) records and may lag recent clearances. Always confirm status with the manufacturer before purchase.

Treatment economics

What practices charge

$250-450 per session; standard protocol 6 sessions over 3 weeks (2x weekly) — courses $1,200-2,400, quarterly maintenance singles after. Cash-pay in nearly all settings.

Consumables & recurring cost

None — no tips, membranes, or per-session fees; gross margin per session is essentially 100% after the marketing cost of acquiring the patient. Annual reality: service contract (~$5k-10k/year post-warranty) plus the ad spend to keep the chair booked.

Ideal for

Best-fit practice

Urogynecology, urology, OB/GYN, pelvic-floor PT, women's-health-leaning medspas; strong in practices serving post-prostatectomy men. Core patient: a woman 40-70 with stress incontinence who has failed Kegels and won't consider surgery — an enormous, under-treated, embarrassed-to-ask demographic that responds to dignified direct marketing.

Compliance

Medical director & delegation

Class II powered muscle stimulator — light-touch oversight in most states, sessions run by MAs or front-office staff after screening; incontinence workups belong with a clinician.

Contraindications & screening

Any implanted metal or electronics in the field — pacemakers, ICDs, copper IUDs (protocol-dependent — verify BTL's current guidance), hip implants near the coil — plus pregnancy, recent pelvic surgery, severe prolapse.

Ownership

Warranty & service

1-year standard; BTL's US service organization is regarded as responsive, and the chair is mechanically simple with few field failures.

Resale & used market

Liquid — chairs move steadily at ~$25k-45k, buoyed by no-consumable economics; values softened as early adopters churn out, making used the smart entry point.